NL-OMON46093
Completed
Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Chronic Migraine - the REGAIN Study - REGAIN [15Q-MC-CGAI]
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- chronic migraine
- Sponsor
- Eli Lilly
- Enrollment
- 54
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
Trial is onging in other countries
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients are 18 to 65 years of age (inclusive) at the time of screening.;Have a diagnosis of chronic migraine as defined by International Headache Society (IHS) International Classification of Headache Disorders (ICHD)\-3 beta.;Migraine onset prior to age 50\.
Exclusion Criteria
- •Are currently enrolled in or have participated within the last 30 days or within 5 half\-lives (whichever is longer) in a clinical trial involving an investigational product.;Current use or prior exposure to LY2951742 or another CGRP antibody;Are currently receiving medication or other treatments for the prevention of migraine headaches.;Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins, or to LY2951742\.;History of persistent daily headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine with brainstem aura (basilar\-type migraine) defined by IHS ICHD\-3 beta.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist TherapyCrohn's Disease10017969NL-OMON38117Janssen-Cilag32
Completed
Phase 3
A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dacetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The dal-GenE trialAcute Coronary syndromearterial disease10028593NL-OMON55786DalCor Pharma UK Ltd276
Completed
Phase 3
A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotrophic Lateral SclerosisNL-OMON48938Orphazyme A/S19
Completed
Phase 3
A Phase 3 Randomized, Placebo-Controlled, Blinded Study to Investigate the Safety and Efficacy of a Topical Gentamicin-Collagen Sponge in Combination with Systemic Antibiotic Therapy in Diabetic Patients with an Infected Foot UlcerNL-OMON43839Innocoll Pharmaceuticals Ltd.8
Completed
Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial Investigating The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery.bypass surgeryCoronary artery bypass grafting10011082NL-OMON50593Sint Antonius Ziekenhuis499